Cytomegalovirus infection post-pancreas-kidney transplantation - Results of antiviral prophylaxis in high-risk patients

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages 503-509

  Fallatah, Samira M ^a   Marquez, Max A ^a   Bazerbachi, Fateh ^a   Schiff, Jeffrey R ^a   Cattral, Mark S ^a   Mcgilvray, Ian D ^a   Norgate, Andrea ^a   Selzner, Markus ^a   Rotstein, Coleman ^a   Husain, Shahid ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cytomegalovirus; Cytomegalovirus prophylaxis; Mismatch; Pancreas after kidney; Simultaneous pancreas kidney; Simultaneous pancreas kidney transplantation

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS PROPHYLAXIS; MISMATCH; PANCREAS AFTER KIDNEY; SIMULTANEOUS PANCREAS- KIDNEY; SIMULTANEOUS PANCREAS- KIDNEY TRANSPLANTATION;

ADULT; ANTIVIRAL AGENTS; CANADA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84881547500     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12138     Document Type: Article

References (22)

1. Axelrod D, McCullough K, Brewer E et al. Kidney and pancreas transplantation in the United States, 1999-2008: the changing face of living donation. Am J Transplant 2010: 10(Part 2): 987.
2. Kaufman DB, Leventhal JR, Gallon LG et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001: 72: 1940.
3. Humar A, Michaels M; On behalf of the AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006: 6: 262.
4. Baehner R, Stiehm E, Landaw S. Overview of Neutropenia. Uptodate; version 19.2. Philadelphia, PA: Wolters Kluwer Health, 2011.
5. Racusen L, Solez K, Colvin R et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
6. Gruessner A, Sutherland D. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005: 19: 433.
7. Kalil A, Mindru C, Botha J, Grant W, Mercer D et al. Risk of cytomegalovirus disease in high-risk liver recipients on valganciclovir prophylaxis: a systematic review and meta- analysis. Liver Transpl 2012: 18: 1440.
8. Bazerbachi F, Selzner M, Boehnert MU et al. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation 2011: 92: 1039.
9. Humar A, Snydmanb D and the AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009: 9(Suppl 4): S78.
10. Preiksaitis J, Brennan D, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005: 5: 218.
11. Raymund R, Razonable R, Limaye A. Cytomegalovirus Infection after Solid Organ Transplantation. In: Bowden R, Ljungman P, Snydman D. Transplant Infections, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2010: 329-361.
12. Humar A, Lebranchu Y, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010: 10: 1228.
13. Lo A, Stratta R, Egidi M. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis 2001: 3: 8.
14. Ricart M, Malaise J and the Euro-SPK Study Group. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005: 20(Suppl 2): ii25.
15. Rayes N, Seehofer D, Neuhaus P. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis. Transpl Int 2007: 20: 974.
16. Becker B, Becker Y, Pirsch J. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002: 39: 1088.
17. Axelrod D, Leventhal J, Kaufman D. Reduction of CMV disease with steroid-free immunosuppression in simultaneous pancreas-kidney transplant recipients. Am J Transplant 2005: 5: 1423.
18. Smets Y, Van Der Pijl JW, van Dissel JT et al. Infectious disease complications of simultaneous pancreas kidney transplantation. Nephrol Dial Transplant 1997: 12: 764.
19. Akalin E, Vinita S, Ames S. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003: 3: 731.
20. Weng F, Patel A, Wanchoo R. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007: 83: 290.
21. Keven K, Basu A, Tan H, Shapiro R. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004: 36: 3107.
22. Paya C, Humar A, Dominguez E; On behalf of the Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004: 4: 611.